… of anti TNF-α could have a healthful role because TNF-α appears to … patient with plaque-type
psoriasis and concomitant chronic HCV, who was treated successfully with anti-TNF agents …

… Tumor necrosis factor (TNF) antagonists have dramatically improved outcomes for patients
with moderate to severe psoriasis. TNF … No safety signals were observed as a specific …

… the safety profile of off‐label uses of TNF antagonists in diseases characterized primarily by
chronic inflammatory arthropathy was … in patients with chronic inflammatory conditions was in …

… Psoriasis is associated with an impaired health-… of psoriasis, represent an established
therapeutic approach for moderate-to-severe plaque psoriasis, with remarkable efficacy and safety …

… data support efficacy and safety of anti-TNF biosimilars for psoriasis treatment. Although IL-…
psoriasis patients, long-term efficacy and safety data of anti-TNF and cost-effectiveness of anti…

… Psoriatic arthritis (PsA) is a heterogeneous, chronic, inflammatory disease, with distinct
classes of therapy now increasingly recommended based on the disease domains …

… such as tumor necrosis factor alpha (TNF-α) inhibitors (1,2). Over the years, numerous …
have demonstrated their efficacy against chronic inflammatory diseases and their relative safety…

… Our study shows promising results for safety of anti-TNFα therapy among people who had a
… or new primary cancers or persistent initial cancers that might influence the prescription of …

… studies (RCTs) have revealed the superiority of anti-IL 17 … biological agents (among the
anti-tumor-necrosis factor) (… records of patients with moderate to severe psoriasis treated with …

… is very limited due to safety concerns and high cost.4 … 16·2 patient years of treatment with
ustekinumab combined with an antitumour necrosis factor‐α agent for recalcitrant psoriasis with …